CISPLATIN, ARA-C AND ETOPOSIDE (PAE) IN THE TREATMENT OF RECURRENT CHILDHOOD BRAIN-TUMORS

被引：31

作者：

CORDEN, BJ

STRAUSS, LC

KILLMOND, T

CARSON, BS

WHARAM, MD

KUMAR, AJ

PIANTADOSI, S

ROBB, PA

PHILLIPS, PC

机构：

[1] JOHNS HOPKINS UNIV HOSP,CTR ONCOL,PEDIAT ONCOL,BALTIMORE,MD 21205

[2] JOHNS HOPKINS UNIV HOSP,CTR ONCOL,BIOSTAT,BALTIMORE,MD 21205

[3] JOHNS HOPKINS UNIV HOSP,DEPT RADIAT ONCOL,BALTIMORE,MD 21205

[4] JOHNS HOPKINS UNIV HOSP,DEPT NEUROSURG,BALTIMORE,MD 21205

[5] JOHNS HOPKINS UNIV HOSP,DEPT NEUROL,BALTIMORE,MD 21205

[6] JOHNS HOPKINS UNIV HOSP,DEPT PEDIAT,BALTIMORE,MD 21205

[7] JOHNS HOPKINS UNIV HOSP,DEPT RADIOL,BALTIMORE,MD 21205

来源：

JOURNAL OF NEURO-ONCOLOGY | 1991年 / 11卷 / 01期

关键词：

CHILDHOOD BRAIN TUMOR; CHEMOTHERAPY;

D O I：

10.1007/BF00166998

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sixteen patients with recurrent childhood brain tumors were treated with intravenous cisplatin, cytosine arabinoside and etoposide (PAE), daily for three days every three to four weeks. Objective responses were observed in 6 of 15 evaluable patients and an additional six patients had stable disease for > 6 months. The tumor-specific response rate for astrocytoma/glioma was 3 of 7 and for medulloblastoma was 2 of 4. The mean progression-free interval was 11.0 months and the hazard rate for progression was 0.085 per patient-month of observation. The most common toxicities were neutropenia and thrombocytopenia. Clinically significant ototoxicity was identified in 7 patients. The activity of PAE chemotherapy for recurrent childhood brain tumors warrants further investigation.

引用

页码：57 / 63

页数：7

共 22 条

[1]

BERGERAT JP, 1981, CANCER RES, V41, P25

[2] A PHASE-II STUDY OF CISPLATIN THERAPY IN RECURRENT CHILDHOOD BRAIN-TUMORS - A REPORT FROM THE CHILDRENS-CANCER-STUDY-GROUP [J].

BERTOLONE, SJ ;

BAUM, ES ;

KRIVIT, W ;

HAMMOND, GD .

JOURNAL OF NEURO-ONCOLOGY, 1989, 7 (01) :5-11

[3] INTENSIVE CHEMOTHERAPY INCLUDING CISPLATIN WITH OR WITHOUT ETOPOSIDE FOR CHILDREN WITH SOFT-TISSUE SARCOMAS [J].

CRIST, WM ;

RANEY, RB ;

RAGAB, A ;

HEYN, R ;

WHARAM, M ;

WEBBER, B ;

JOHNSTON, J ;

BELTANGADY, M .

MEDICAL AND PEDIATRIC ONCOLOGY, 1987, 15 (02) :51-57

[4]

DIEZ B, 1985, CANCER TREAT REP, V69, P911

[5]

DURAND RE, 1987, CANCER TREAT REP, V71, P673

[6]

EDWARDS MS, 1980, CANCER TREAT REP, V64, P1179

[7]

FALKSON G, 1975, CANCER, V35, P1141, DOI 10.1002/1097-0142(197504)35:4<1141::AID-CNCR2820350418>3.0.CO

[8]

2-3

[9]

FRIEDMAN HS, 1988, CANCER RES, V48, P4189

[10]

Granowetter L, 1983, J Neurooncol, V1, P293, DOI 10.1007/BF00165711

← 1 2 3 →